Meikang Bio released its 2026 interim report. First-half operating revenue was 828 million yuan, up 12.5% year on year. Net profit attributable to the parent was 61.95 million yuan, up 9.0% year on year. Non-GAAP net profit attributable to the parent was 44.24 million yuan, up 47.3% year on year. In the second quarter, operating revenue was 452 million yuan, up 24.8% year on year, and non-GAAP net profit attributable to the parent was 21.09 million yuan, up 125.0% year on year. As of the end of the second quarter, total assets were 3.709 billion yuan, up 1.5% from the end of the previous year, and net assets attributable to the parent were 3.003 billion yuan, up 1.7% from the end of the previous year. The company continues to focus on the research, development, production and sales of in vitro diagnostic products, and has obtained 523 registration certificates for in vitro diagnostic reagent products and 55 registration certificates for in vitro diagnostic instruments.
Ningbo MedicalSystem Biotechnology Co LtdH1 non-GAAP net profit up 47.3% YoY, Q2 up 125% YoY
